Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
22 October 2015
Header
Header image
From our blog

From our blog

Securing the basis for collaboration
22 October 2015 by Richard Bergström

Across Europe, by the end of June 2016, EFPIA member companies will disclose payments made to health professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards.

Read more

From our blog

A Pentagram Model with Patient Groups (Guest Blog)
22 October 2015 by Cees Smit (EGAN)

During the Health Collaboration Summit on October 28 and 29 in Brussels, we are going to discuss the industry-patient relationship. In a recent Dutch publication, called ‘The power of the patient, boss of your own disease,’ my colleague Annemarie de Knecht – van Eekelen and myself withdrew from referring to the patient as ‘the third party’ in healthcare, as part of a triumvirate including healthcare providers and healthcare insurers.

Read more

From our blog

IMI2’s BD4BO Has the Power to Renew Hope and Transform Lives (Guest Blog)
22 October 2015 by Stephan Korte (Novartis)

Jointly funded to the tune of €3.276 billion – by the pharmaceutical industry and the EU – the Innovative Medicines Initiative 2 (IMI2) represents a haven of hope for Europe’s patient population.

Read more

From our blog

Why we need an open infrastructure for proactive patient engagement throughout the lifecycle of a product (Guest Blog)
22 October 2015 by Mathieu Boudes and Yann Le Cam (EURORDIS – Rare Diseases Europe)

The goal of patient engagement throughout the development of medicines is to have better, more effective therapeutic solutions for patients and to produce them faster and more efficiently. 

Read more

From our blog

A Patient Drive to Shape their Relationship with Industry Would Benefit All (Guest Blog)
22 October 2015 by Audrey Craven (European Federation of Neurological Associations)

We live in exciting times: innovation is booming; the pharmaceutical industry’s pipelines are full of promise; and unmet medical needs are being addressed. To carry on further down this path towards better healthcare provision overall, the pharmaceutical industry is rightly pursuing the use of big data to better target medicines.

Read more

From our blog

EFPIA’s Disclosure Code: The Benefits and Limitations of Transparency (Guest Blog)
22 October 2015 by Brennan Jacoby

I am not a healthcare professional, nor do I work in the pharmaceutical industry. I am a philosopher who researches trust, and a citizen who has, unfortunately, had more than his fair share of medical emergencies. As such, I am increasingly convinced that transparency is an incredibly important, but limited, tool for building trust where health is concerned.

Read more

Events calendar

Events Calendar

EFPIA Health Collaboration Summit 28-29 October 2015
From 28/10/2015 to 29/10/2015 (Brussels)

The event will bring together senior figures from patient organisations, healthcare systems and industry to discuss outcomes driven, sustainable healthcare in Europe and the role of transparency in developing effective working relationships, capacity building and governance.

In order to share best practice on multi-stakeholder collaborations that benefit patients and healthcare systems, EFPIA and the Patient Think Tank are establishing the Health Collaboration Award.

The Award is open to multi-stakeholder collaborative projects on local, national and EU level that benefit patients. Entrants must include patient organisations and industry partners.

 

 

 

 

 

Please note that the event is full and registration is now closed. Please note that submissions for the Awards closed on 5 October. 

For more information, click here or contact zsofia.bakonyi@efpia.eu.

Read more

Events Calendar

Emerging Medicinal Products – from laboratory to patient use
On 14/12/2015 (De Vere Centre, 1 Westferry Circus, Canary Wharf, London)

The fourth annual regulatory policy summit has been organised by EBE and the European Medicines Agency (EMA).

 

 

 

Read more

Documents

From our blog

Eco-Pharmaco-Stewardship (EPS) - Pillar 1 - Research & development: intelligence-led assessment of pharmaceuticals in the environment (iPiE)
09 October 2015 (Publications)

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail